TY - JOUR
T1 - Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
AU - Mielke, Michelle M.
AU - Anderson, Matthew
AU - Ashford, J. Wesson
AU - Jeromin, Andreas
AU - Lin, Pei Jung
AU - Rosen, Allyson
AU - Tyrone, Jamie
AU - VandeVrede, Lawren
AU - Willis, Deanna
AU - Hansson, Oskar
AU - Khachaturian, Ara S.
AU - Schindler, Suzanne E.
AU - Weiss, Joan
AU - Batrla, Richard
AU - Bozeat, Sasha
AU - Dwyer, John R.
AU - Holzapfel, Drew
AU - Jones, Daryl Rhys
AU - Murray, James F.
AU - Partrick, Katherine A.
AU - Scholler, Emily
AU - Vradenburg, George
AU - Young, Dylan
AU - Braunstein, Joel B.
AU - Burnham, Samantha C.
AU - de Oliveira, Fabricio Ferreira
AU - Hu, Yan Helen
AU - Mattke, Soeren
AU - Merali, Zul
AU - Monane, Mark
AU - Sabbagh, Marwan Noel
AU - Shobin, Eli
AU - Weiner, Michael W.
AU - Udeh-Momoh, Chinedu T.
N1 - Publisher Copyright:
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2024/11
Y1 - 2024/11
N2 - Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer's Disease BBM Workgroup convened to address these challenges and provide recommendations that underscore the importance of evidence-based guidelines, improved training for health-care professionals, patient empowerment through informed decision making, and the necessity of community-based studies to understand BBM performance in real-world populations. Multi-stakeholder engagement is essential to implement these recommendations and ensure credible guidance and education are accessible to all stakeholders.
AB - Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer's Disease BBM Workgroup convened to address these challenges and provide recommendations that underscore the importance of evidence-based guidelines, improved training for health-care professionals, patient empowerment through informed decision making, and the necessity of community-based studies to understand BBM performance in real-world populations. Multi-stakeholder engagement is essential to implement these recommendations and ensure credible guidance and education are accessible to all stakeholders.
KW - Alzheimer's disease
KW - amyloid
KW - biomarker
KW - blood-based biomarkers
KW - clinical implementation
KW - clinical practice
KW - cognitive impairment
KW - disease-modifying treatment
KW - ethics
KW - patient journey
KW - primary care
KW - secondary care
UR - http://www.scopus.com/inward/record.url?scp=85205677917&partnerID=8YFLogxK
U2 - 10.1002/alz.14150
DO - 10.1002/alz.14150
M3 - Article
C2 - 39369283
AN - SCOPUS:85205677917
SN - 1552-5260
VL - 20
SP - 8209
EP - 8215
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 11
ER -